Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
EMERYVILLE, Calif., Sept. 20, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Ladenburg Thalmann 2016 Healthcare Conference, and will participate in a fireside chat at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable Series.
Ladenburg Thalmann 2016 Healthcare Conference -- Zogenix Presentation Details
| Date: | Tuesday, September 27, 2016 | |||
| Time: | 4:00 pm Eastern Time / 1:00 pm Pacific Time | |||
| Location: | New York, NY | |||
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology -- Zogenix Presentation Details
| Date: | Wednesday, September 28, 2016 | |||||
| Time: | 10:00 am Eastern Time / 7:00 am Pacific Time | |||||
| Location: | New York, NY | |||||
The presentations will be webcast live and can be accessed on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
